{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:40:33Z","timestamp":1790833233504,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T00:00:00Z","timestamp":1375401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T00:00:00Z","timestamp":1375401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/ncomms3246","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T09:49:57Z","timestamp":1375436997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Alzheimer\u2019s disease mutations in APP but not \u03b3-secretase modulators affect epsilon-cleavage-dependent AICD production"],"prefix":"10.1038","volume":"4","author":[{"given":"Mitko","family":"Dimitrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Ren\u00e9","family":"Alattia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lemmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajwinder","family":"Lehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Fligier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemila","family":"Houacine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishrut","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Dal Peraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Beher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Fraering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,2]]},"reference":[{"key":"BFncomms3246_CR1","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245\u20134249 (1985).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms3246_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S0140-6736(87)91754-5","volume":"1","author":"NK Robakis","year":"1987","unstructured":"Robakis, N. K. et al. Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet 1, 384\u2013385 (1987).","journal-title":"Lancet"},{"key":"BFncomms3246_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0140-6736(89)91725-X","volume":"1","author":"AM Goate","year":"1989","unstructured":"Goate, A. M. et al. Predisposing locus for Alzheimer's disease on chromosome 21. Lancet 1, 352\u2013355 (1989).","journal-title":"Lancet"},{"key":"BFncomms3246_CR4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754\u2013760 (1995).","journal-title":"Nature"},{"key":"BFncomms3246_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1749-6632.1993.tb23037.x","volume":"695","author":"C Haass","year":"1993","unstructured":"Haass, C. et al. Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann. NY Acad. Sci. 695, 109\u2013116 (1993).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFncomms3246_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/19083","volume":"398","author":"B De Strooper","year":"1999","unstructured":"De Strooper, B. et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518\u2013522 (1999).","journal-title":"Nature"},{"key":"BFncomms3246_CR7","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1074\/jbc.M110.142521","volume":"286","author":"N Bot","year":"2011","unstructured":"Bot, N., Schweizer, C., Ben Halima, S. & Fraering, P. C. Processing of the synaptic cell adhesion molecule neurexin-3beta by Alzheimer disease alpha- and gamma-secretases. J. Biol. Chem. 286, 2762\u20132773 (2011).","journal-title":"J. Biol. Chem."},{"key":"BFncomms3246_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.neulet.2006.04.018","volume":"402","author":"K Uemura","year":"2006","unstructured":"Uemura, K. et al. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci. Lett. 402, 278\u2013283 (2006).","journal-title":"Neurosci. Lett."},{"key":"BFncomms3246_CR9","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1038\/emboj.2011.372","volume":"30","author":"Y Ohki","year":"2011","unstructured":"Ohki, Y. et al. Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J. 30, 4815\u20134824 (2011).","journal-title":"EMBO J."},{"key":"BFncomms3246_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ncomms1129","volume":"1","author":"K Uemura","year":"2010","unstructured":"Uemura, K. et al. Substrate docking to gamma-secretase allows access of gamma-secretase modulators to an allosteric site. Nat. Commun. 1, 130 (2010).","journal-title":"Nat. Commun."},{"key":"BFncomms3246_CR11","doi-asserted-by":"publisher","first-page":"6889","DOI":"10.1073\/pnas.0602321103","volume":"103","author":"VK Lazarov","year":"2006","unstructured":"Lazarov, V. K. et al. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc. Natl Acad. Sci. USA 103, 6889\u20136894 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms3246_CR12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1471-4159.2007.05041.x","volume":"104","author":"M Cacquevel","year":"2008","unstructured":"Cacquevel, M. et al. Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J. Neurochem. 104, 210\u2013220 (2008).","journal-title":"J. Neurochem."},{"key":"BFncomms3246_CR13","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/emboj.2012.79","volume":"31","author":"L Chavez-Gutierrez","year":"2012","unstructured":"Chavez-Gutierrez, L. et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 2261\u20132274 (2012).","journal-title":"EMBO J."},{"key":"BFncomms3246_CR14","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/nm1295-1291","volume":"1","author":"C Haass","year":"1995","unstructured":"Haass, C. et al. The Swedish mutation causes early-onset Alzheimer's disease by [beta]-secretase cleavage within the secretory pathway. Nat. Med. 1, 1291\u20131296 (1995).","journal-title":"Nat. Med."},{"key":"BFncomms3246_CR15","doi-asserted-by":"publisher","first-page":"24294","DOI":"10.1074\/jbc.M211161200","volume":"278","author":"T Sato","year":"2003","unstructured":"Sato, T. et al. Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. J. Biol. Chem. 278, 24294\u201324301 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFncomms3246_CR16","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/hmg\/6.12.2087","volume":"6","author":"CB Eckman","year":"1997","unstructured":"Eckman, C. B. et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum. Mol. Genet. 6, 2087\u20132089 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"BFncomms3246_CR17","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1093\/hmg\/9.18.2589","volume":"9","author":"S Kumar-Singh","year":"2000","unstructured":"Kumar-Singh, S. et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum. Mol. Genet. 9, 2589\u20132598 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"BFncomms3246_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ana.22365","volume":"69","author":"NF Schor","year":"2011","unstructured":"Schor, N. F. What the halted phase III \u03b3-secretase inhibitor trial may (or may not) be telling us. Ann. Neurol. 69, 237\u2013239 (2011).","journal-title":"Ann. Neurol."},{"key":"BFncomms3246_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/35102591","volume":"414","author":"S Weggen","year":"2001","unstructured":"Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212\u2013216 (2001).","journal-title":"Nature"},{"key":"BFncomms3246_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1172\/JCI18162","volume":"112","author":"JL Eriksen","year":"2003","unstructured":"Eriksen, J. L. et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440\u2013449 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFncomms3246_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nature07055","volume":"453","author":"TL Kukar","year":"2008","unstructured":"Kukar, T. L. et al. Substrate-targeting gamma-secretase modulators. Nature 453, 925\u2013929 (2008).","journal-title":"Nature"},{"key":"BFncomms3246_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1021\/cn200098p","volume":"2","author":"CJ Crump","year":"2011","unstructured":"Crump, C. J. et al. Piperidine acetic acid based gamma-secretase modulators directly bind to Presenilin-1. ACS Chem. Neurosci. 2, 705\u2013710 (2011).","journal-title":"ACS Chem. Neurosci."},{"key":"BFncomms3246_CR23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. & Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702\u2013716 (2010).","journal-title":"Lancet Neurol."},{"key":"BFncomms3246_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.2174\/157015911798376352","volume":"9","author":"B Bulic","year":"2011","unstructured":"Bulic, B. et al. Chemical biology, molecular mechanism and clinical perspective of gamma-secretase modulators in Alzheimer's disease. Curr. Neuropharmacol. 9, 598\u2013622 (2011).","journal-title":"Curr. Neuropharmacol."},{"key":"BFncomms3246_CR25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1084\/jem.20070876","volume":"204","author":"J O'Neil","year":"2007","unstructured":"O'Neil, J. et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 204, 1813\u20131824 (2007).","journal-title":"J. Exp. Med."},{"key":"BFncomms3246_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1042\/bj3550869","volume":"355","author":"DM Walsh","year":"2001","unstructured":"Walsh, D. M., Hartley, D. M., Condron, M. M., Selkoe, D. J. & Teplow, D. B. In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease. Biochem. J. 355, 869\u2013877 (2001).","journal-title":"Biochem. J."},{"key":"BFncomms3246_CR27","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.1219988","volume":"336","author":"PJ Barrett","year":"2012","unstructured":"Barrett, P. J. et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168\u20131171 (2012).","journal-title":"Science"},{"key":"BFncomms3246_CR28","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/bioinformatics\/bts357","volume":"28","author":"AC Dahl","year":"2012","unstructured":"Dahl, A. C., Chavent, M. & Sansom, M. S. Bendix: intuitive helix geometry analysis and abstraction. Bioinformatics 28, 2193\u20132194 (2012).","journal-title":"Bioinformatics"},{"key":"BFncomms3246_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.tips.2010.05.007","volume":"31","author":"H Zettl","year":"2010","unstructured":"Zettl, H., Weggen, S., Schneider, P. & Schneider, G. Exploring the chemical space of gamma-secretase modulators. Trends Pharmacol. Sci. 31, 402\u2013410 (2010).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFncomms3246_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0896-6273(01)00512-8","volume":"32","author":"WG Annaert","year":"2001","unstructured":"Annaert, W. G. et al. Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron 32, 579\u2013589 (2001).","journal-title":"Neuron"},{"key":"BFncomms3246_CR31","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1096\/fj.11-201368","volume":"26","author":"C Esselens","year":"2012","unstructured":"Esselens, C. et al. Peptides based on the presenilin-APP binding domain inhibit APP processing and Abeta production through interfering with the APP transmembrane domain. FASEB J. 26, 3765\u20133778 (2012).","journal-title":"FASEB J."},{"key":"BFncomms3246_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejcb.2011.01.017","volume":"91","author":"D Kaden","year":"2012","unstructured":"Kaden, D., Munter, L. M., Reif, B. & Multhaup, G. The amyloid precursor protein and its homologues: structural and functional aspects of native and pathogenic oligomerization. Eur. J. Cell Biol. 91, 234\u2013239 (2012).","journal-title":"Eur. J. Cell Biol."},{"key":"BFncomms3246_CR33","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1021\/bi300303g","volume":"51","author":"O Holmes","year":"2012","unstructured":"Holmes, O., Paturi, S., Ye, W., Wolfe, M. S. & Selkoe, D. J. Effects of membrane lipids on the activity and processivity of purified gamma-secretase. Biochemistry 51, 3565\u20133575 (2012).","journal-title":"Biochemistry"},{"key":"BFncomms3246_CR34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/bit.24851","volume":"110","author":"JR Alattia","year":"2013","unstructured":"Alattia, J. R. et al. Highly efficient production of the Alzheimer's gamma-Secretase integral membrane protease complex by a multi-gene stable integration approach. Biotechnol. Bioeng. 110, 1995\u20132005 (2013).","journal-title":"Biotechnol. Bioeng."},{"key":"BFncomms3246_CR35","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1096\/fj.10-174078","volume":"25","author":"JR Alattia","year":"2011","unstructured":"Alattia, J. R. et al. Mercury is a direct and potent gamma-secretase inhibitor affecting Notch processing and development in Drosophila. FASEB J. 25, 2287\u20132295 (2011).","journal-title":"FASEB J."},{"key":"BFncomms3246_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33\u201338 27-8 (1996).","journal-title":"J. Mol. Graph."},{"key":"BFncomms3246_CR37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","volume":"31","author":"K Vanommeslaeghe","year":"2010","unstructured":"Vanommeslaeghe, K. et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671\u2013690 (2010).","journal-title":"J. Comput. Chem."},{"key":"BFncomms3246_CR38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","volume":"26","author":"JC Phillips","year":"2005","unstructured":"Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781\u20131802 (2005).","journal-title":"J. Comput. Chem."},{"key":"BFncomms3246_CR39","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1021\/jp101759q","volume":"114","author":"JB Klauda","year":"2010","unstructured":"Klauda, J. B. et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J. Phys. Chem. B 114, 7830\u20137843 (2010).","journal-title":"J. Phys. Chem. B"},{"key":"BFncomms3246_CR40","doi-asserted-by":"publisher","first-page":"W270","DOI":"10.1093\/nar\/gkr366","volume":"39","author":"A Grosdidier","year":"2011","unstructured":"Grosdidier, A., Zoete, V. & Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 39, W270\u2013W277 (2011).","journal-title":"Nucleic Acids Res."},{"key":"BFncomms3246_CR41","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1002\/jcc.21797","volume":"32","author":"A Grosdidier","year":"2011","unstructured":"Grosdidier, A., Zoete, V. & Michielin, O. Fast docking using the CHARMM force field with EADock DSS. J. Comput. Chem. 32, 2149\u20132159 (2011).","journal-title":"J. Comput. Chem."},{"key":"BFncomms3246_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/prot.23165","volume":"80","author":"HS Lee","year":"2012","unstructured":"Lee, H.S. & Zhang, Y. BSP-SLIM: a blind low-resolution ligand-protein docking approach using predicted protein structures. Proteins 80, 93\u2013110 (2012).","journal-title":"Proteins"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms3246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms3246","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms3246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T23:04:53Z","timestamp":1715814293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms3246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,10,16]]}},"alternative-id":["BFncomms3246"],"URL":"https:\/\/doi.org\/10.1038\/ncomms3246","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,2]]},"assertion":[{"value":"13 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.B. and I.H. were full-time employees of Merck Serono S.A. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2246"}}